![]() |
|
![]() |
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsors and Collaborators: |
The Cooper Institute Chemi Nutra |
Information provided by: | The Cooper Institute |
ClinicalTrials.gov Identifier: | NCT00153790 |
The primary aim is to examine whether the intake of PhosphoLEAN is effective in aiding a cohort of women in losing weight. Participants taking the supplement will have significantly greater improvement in study outcomes than those taking the placebo.
Condition | Intervention | Phase |
Weight Loss |
Drug: PhosphoLean |
Phase I |
MedlinePlus related topics: | Weight Control |
ChemIDplus related topics: | Epigallocatechin gallate Proteins, soy Lecithin Ethanolamine |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Safety/Efficacy Study |
Official Title: | The Effect of Soy Lecithin-Derived N-Oleoyl-Phosphatidyl-Ethanolamine (NOPE) and Green Tea-Derived Epigallocatechin Gallate (EGCG) on Indices of Weight Loss and Appetite Suppression |
Estimated Enrollment: | 60 |
Study Start Date: | April 2005 |
Estimated Study Completion Date: | May 2006 |
Participants will be randomized to either a control or treatment group taking the dietary supplement containing a soy lecithin-derived N-oleoyl-phosphatidyl-ethanolamine (NOPE) and caffeine free Green Tea-derived epigallocathchin gallate (EGCG) whose trade name is PhosphoLean. The outcome is to determine the effects on indices of weight loss and appetite suppression. Participants will return at 6, 12, and 16 weeks for clinical measures.
Ages Eligible for Study: | 30 Years to 45 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
United States, Texas | |||||
The Cooper Institute | |||||
Dallas, Texas, United States, 75230 |
The Cooper Institute |
Chemi Nutra |
Principal Investigator: | Conrad Earnest, PhD | The Cooper Institute |
Study ID Numbers: | CI0151 |
First Received: | September 7, 2005 |
Last Updated: | March 30, 2006 |
ClinicalTrials.gov Identifier: | NCT00153790 |
Health Authority: | United States: Institutional Review Board |
|
|
![]() |